## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 1 OF 1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (If known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,608,057 B2	08-19-2003	Cywin et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>1</sup>		
	2	ALTERI E et al. 1993 "CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity" Antimicrob Agents Chemother 37:2087- 2092.			
	3	MANOURY B. et al. 2002 "Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP" Nature Immunology 3:169-174.			
	4	RIESE, R.J. et al. 1998 "Cathepsin S activity regulates antigen presentation and immunity" J Clin Invest 101:2351-2363.			

7721934 082709

Examiner Signature	Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.